Please login to the form below

Not currently logged in
Email:
Password:

deflazacort

This page shows the latest deflazacort news and features for those working in and with pharma, biotech and healthcare.

FDA reviewer unimpressed with PTC’s Translarna

FDA reviewer unimpressed with PTC’s Translarna

saying its commercial operations were already in gear following the FDA’s approval of Emflaza (deflazacort) for DMD earlier this year.

Latest news

  • Connecting the dots Connecting the dots

    Not just any drug mind you - a decades-old corticosterioid called Emflaza (deflazacort) that is available elsewhere for about $1, 500 per year.

  • Marathon pauses Emflaza launch amid pricing furore Marathon pauses Emflaza launch amid pricing furore

    In a nutshell, they want Marathon to justify its claim that the cost of developing Emflaza for DMD warrants that price tag, given that deflazacort a is "widely available abroad for

  • FDA approves first steroid for Duchenne muscular dystrophy FDA approves first steroid for Duchenne muscular dystrophy

    Emflaza (deflazacort) is the first corticosteroid to be approved by the FDA to treat DMD, said the US agency in a statement. ... Complicating the picture is that deflazacort has been available outside the US for decades and patients have been able to

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Deal Watch March 2017 Deal Watch March 2017

    230. Marathon. PTC Therapeutics. Product acquisition. Emflaza (deflazacort), marketed for Duchenne Muscular Dystrophy.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Six Degrees Medical Consulting

Partnering with top global pharmaceutical companies, we push the boundaries to create meaningful, impactful and lasting learning opportunities. We leverage...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics